PubRank

Amy Hsu

Author PubWeight™ 39.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008 8.17
2 Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003 5.34
3 Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010 2.05
4 Hospital characteristics associated with feeding tube placement in nursing home residents with advanced cognitive impairment. JAMA 2010 1.91
5 Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2009 1.64
6 Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 2013 1.54
7 Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics 2010 1.30
8 A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J Neurochem 2004 1.04
9 Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old. Am J Cardiol 2003 0.98
10 Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 2007 0.98
11 Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO cultures. Biotechnol Bioeng 2010 0.92
12 Rapid protein production using CHO stable transfection pools. Biotechnol Prog 2010 0.90
13 Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation 2010 0.90
14 Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol Prog 2011 0.88
15 Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies. Am J Cardiol 2007 0.87
16 Coronary abnormalities in hyper-IgE recurrent infection syndrome: depiction at coronary MDCT angiography. AJR Am J Roentgenol 2009 0.85
17 The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006 0.82
18 The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V. Am Heart J 2009 0.80
19 Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials. Am J Cardiol 2010 0.79
20 Progression of coronary atherosclerosis in African-American patients. Cardiovasc Diagn Ther 2013 0.79
21 Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open 2013 0.79
22 Bone density and fractures in autosomal dominant hyper IgE syndrome. J Clin Immunol 2014 0.78
23 Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm 2010 0.78
24 The impact of changing antiseptic skin preparation agent used for cardiac implantable electronic device (CIED) procedures on the risk of infection. Pacing Clin Electrophysiol 2014 0.77
25 Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention. J Invasive Cardiol 2008 0.77
26 The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? Postgrad Med 2014 0.77
27 Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. J Mol Biol 2002 0.76
28 RNase P ribozymes for the studies and treatment of human cytomegalovirus infections. J Clin Virol 2002 0.76